RT Journal Article
SR Electronic
T1 Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.19.21268028
DO 10.1101/2021.12.19.21268028
A1 Viana, Raquel
A1 Moyo, Sikhulile
A1 Amoako, Daniel G
A1 Tegally, Houriiyah
A1 Scheepers, Cathrine
A1 Althaus, Christian L
A1 Anyaneji, Ugochukwu J
A1 Bester, Phillip A
A1 Boni, Maciej F
A1 Chand, Mohammed
A1 Choga, Wonderful T
A1 Colquhoun, Rachel
A1 Davids, Michaela
A1 Deforche, Koen
A1 Doolabh, Deelan
A1 Engelbrecht, Susan
A1 Everatt, Josie
A1 Giandhari, Jennifer
A1 Giovanetti, Marta
A1 Hardie, Diana
A1 Hill, Verity
A1 Hsiao, Nei-Yuan
A1 Iranzadeh, Arash
A1 Ismail, Arshad
A1 Joseph, Charity
A1 Joseph, Rageema
A1 Koopile, Legodile
A1 Pond, Sergei L Kosakovsky
A1 Kraemer, Moritz UG
A1 Kuate-Lere, Lesego
A1 Laguda-Akingba, Oluwakemi
A1 Lesetedi-Mafoko, Onalethatha
A1 Lessells, Richard J
A1 Lockman, Shahin
A1 Lucaci, Alexander G
A1 Maharaj, Arisha
A1 Mahlangu, Boitshoko
A1 Maponga, Tongai
A1 Mahlakwane, Kamela
A1 Makatini, Zinhle
A1 Marais, Gert
A1 Maruapula, Dorcas
A1 Masupu, Kereng
A1 Matshaba, Mogomotsi
A1 Mayaphi, Simnikiwe
A1 Mbhele, Nokuzola
A1 Mbulawa, Mpaphi B
A1 Mendes, Adriano
A1 Mlisana, Koleka
A1 Mnguni, Anele
A1 Mohale, Thabo
A1 Moir, Monika
A1 Moruisi, Kgomotso
A1 Mosepele, Mosepele
A1 Motsatsi, Gerald
A1 Motswaledi, Modisa S
A1 Mphoyakgosi, Thongbotho
A1 Msomi, Nokukhanya
A1 Mwangi, Peter N
A1 Naidoo, Yeshnee
A1 Ntuli, Noxolo
A1 Nyaga, Martin
A1 Olubayo, Lucier
A1 Pillay, Sureshnee
A1 Radibe, Botshelo
A1 Ramphal, Yajna
A1 Ramphal, Upasana
A1 San, James E
A1 Scott, Lesley
A1 Shapiro, Roger
A1 Singh, Lavanya
A1 Smith-Lawrence, Pamela
A1 Stevens, Wendy
A1 Strydom, Amy
A1 Subramoney, Kathleen
A1 Tebeila, Naume
A1 Tshiabuila, Derek
A1 Tsui, Joseph
A1 van Wyk, Stephanie
A1 Weaver, Steven
A1 Wibmer, Constantinos K
A1 Wilkinson, Eduan
A1 Wolter, Nicole
A1 Zarebski, Alexander E
A1 Zuze, Boitumelo
A1 Goedhals, Dominique
A1 Preiser, Wolfgang
A1 Treurnicht, Florette
A1 Venter, Marietje
A1 Williamson, Carolyn
A1 Pybus, Oliver G
A1 Bhiman, Jinal
A1 Glass, Allison
A1 Martin, Darren P
A1 Rambaut, Andrew
A1 Gaseitsiwe, Simani
A1 von Gottberg, Anne
A1 de Oliveira, Tulio
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268028.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in southern Africa has been characterised by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, whilst the second and third waves were driven by the Beta and Delta variants respectively1–3. In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng Province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for carrying over 30 mutations in the spike glycoprotein, predicted to influence antibody neutralization and spike function4. Here, we describe the genomic profile and early transmission dynamics of Omicron, highlighting the rapid spread in regions with high levels of population immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research reported in this publication was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation. CA received funding from the European Union Horizon 2020 research and innovation programme project EpiPose (No 101003688). DPM was funded by the Wellcome Trust (222574/Z/21/Z). RC & AR acknowledge support from the Wellcome Trust (Collaborators Award 206298/Z/17/Z ARTIC network) and AR from the European Research Council (grant agreement number 725422 ReservoirDOCS). VH was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grant number BB/M010996/1). AEZ, JT, MUGK, OGP acknowledge support from the Oxford Martin School. MUGK acknowledges support from the Rockefeller Foundation, Google.org, and the European Horizon 2020 programme MOOD (#874850). MV and the ZARV members, UP was funded through the ANDEMIA G7 Global Health Concept: contributions to improvement of International Health, COVID19 funds through the Robert Koch Institute. The genomic sequencing at UCT/NHLS is funded from the South African Medical Research Council and Department of Science and Innovation; and by the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI Africa) which is supported by core funding from the Wellcome Trust [203135/Z/16/Z and 222754]. CW and JNB are funded by the EDCTP (RADIATES Consortium; RIA2020EF 3030). Sequencing activities at the NICD were supported by: a conditional grant from the South African National Department of Health as part of the emergency COVID 19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (grant number 5 U01IP001048 05 00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub award from the Bill and Melinda Gates Foundation grant number INV 018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); the South African Medical Research Council (Reference number SHIPNCD 76756); the UK Department of Health and Social Care, managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. The genomic sequencing in Botswana was supported by the Foundation for Innovative New Diagnostics and Fogarty International Center (5D43TW009610), NIH (5K24AI131924 04; 5K24AI131928 05), as well in kind support from the Botswana government through the Ministry of Health & Wellness and Presidential COVID 19 Task Force. SM was supported in part by the Bill & Melinda Gates Foundation [036530].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The genomic surveillance in South Africa was approved by the University of KwaZulu Natal Biomedical Research Ethics Committee (BREC/00001510/2020), the University of the Witwatersrand Human Research Ethics Committee (HREC) (M180832), Stellenbosch University HREC (N20/04/008_COVID-19), University of Cape Town HREC (383/2020), University of Pretoria HREC (H101/17) and the University of the Free State Health Sciences Research Ethics Committee (UFS HSD2020/1860/2710). The genomic sequencing in Botswana was conductedas part of the national vaccine roll-out plan and was approved by the Health Research and Development Committee (Health Research Ethics body, HRDC#00948 and HRDC#00904). Individual participant consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomes generated in this research at public available at GISAID. The short reads are public available at the Short Read Archives of NCBI.